EV-077

EV-077

 

EV-077 is in development as a potential pharmaceutical for the treatment of  diabetic nephropathy and other diabetic complications. It is in Phase II clinical studies.

In 2013, Evolva out-licensed EV-077 to Serodus (Oslo, Norway). Serodus aims to bring EV-077 through Phase II and then decide whether or not to partner for the final clinical trials and commercialisation. Evolva is entitled to clinical and regulatory milestones as well as a single-digit royalty on sales. If Serodus sublicenses EV-077 then Evolva will receive up to 30% of Serodus’ total licensing income.

As of Q2 2015 Serodus continues active development of EV-077.

  • Resveratrol’s effect on glucose control & insulin sensitivity. A meta-analysis.

    A meta analysis found that resveratrol can have a positive impact on glucose control and insulin sensitivity.

    Amer. J Clin. Nutrition
  • Making alliances work

    Evolva believes that good collaborations require good communication, good science and engineering, and of course good results.

    Harvard Bus. Review
More articles
cancel

Sign up to receive our
Press Releases!

Sign up